328 related articles for article (PubMed ID: 15793255)
21. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Buchanan TA; Xiang AH; Peters RK; Kjos SL; Marroquin A; Goico J; Ochoa C; Tan S; Berkowitz K; Hodis HN; Azen SP
Diabetes; 2002 Sep; 51(9):2796-803. PubMed ID: 12196473
[TBL] [Abstract][Full Text] [Related]
22. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
Snitker S; Watanabe RM; Ani I; Xiang AH; Marroquin A; Ochoa C; Goico J; Shuldiner AR; Buchanan TA;
Diabetes Care; 2004 Jun; 27(6):1365-8. PubMed ID: 15161789
[TBL] [Abstract][Full Text] [Related]
23. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
[TBL] [Abstract][Full Text] [Related]
24. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Ciaraldi TP; Kong AP; Chu NV; Kim DD; Baxi S; Loviscach M; Plodkowski R; Reitz R; Caulfield M; Mudaliar S; Henry RR
Diabetes; 2002 Jan; 51(1):30-6. PubMed ID: 11756319
[TBL] [Abstract][Full Text] [Related]
25. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.
Venditti EM; Bray GA; Carrion-Petersen ML; Delahanty LM; Edelstein SL; Hamman RF; Hoskin MA; Knowler WC; Ma Y;
Int J Obes (Lond); 2008 Oct; 32(10):1537-44. PubMed ID: 18711387
[TBL] [Abstract][Full Text] [Related]
26. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
27. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
28. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
29. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function.
Xiang AH; Peters RK; Kjos SL; Goico J; Ochoa C; Marroquin A; Tan S; Hodis HN; Azen SP; Buchanan TA
J Clin Endocrinol Metab; 2004 Jun; 89(6):2846-51. PubMed ID: 15181067
[TBL] [Abstract][Full Text] [Related]
31. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Phillips SA; Ciaraldi TP; Kong AP; Bandukwala R; Aroda V; Carter L; Baxi S; Mudaliar SR; Henry RR
Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
[TBL] [Abstract][Full Text] [Related]
32. Association of Intensive Lifestyle and Metformin Interventions With Frailty in the Diabetes Prevention Program Outcomes Study.
Hazuda HP; Pan Q; Florez H; Luchsinger JA; Crandall JP; Venditti EM; Golden SH; Kriska AM; Bray GA
J Gerontol A Biol Sci Med Sci; 2021 Apr; 76(5):929-936. PubMed ID: 33428709
[TBL] [Abstract][Full Text] [Related]
33. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
34. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
[TBL] [Abstract][Full Text] [Related]
35. A retrospective review of thiazolidinediones with development of a troglitazone conversion protocol.
Lindsey C; Graham M; McMurphy J
ScientificWorldJournal; 2003 Jun; 3():477-83. PubMed ID: 12847298
[TBL] [Abstract][Full Text] [Related]
36. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
[TBL] [Abstract][Full Text] [Related]
37. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
38. Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.
Levin K; Hother-Nielsen O; Henriksen JE; Beck-Nielsen H
Diabetes Care; 2004 Jan; 27(1):148-54. PubMed ID: 14693981
[TBL] [Abstract][Full Text] [Related]
39. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
Diabetes Prevention Program Research Group
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
[TBL] [Abstract][Full Text] [Related]
40. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.
Aroda VR; Christophi CA; Edelstein SL; Zhang P; Herman WH; Barrett-Connor E; Delahanty LM; Montez MG; Ackermann RT; Zhuo X; Knowler WC; Ratner RE;
J Clin Endocrinol Metab; 2015 Apr; 100(4):1646-53. PubMed ID: 25706240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
